Mark Leuchtenberger joined Acusphere, Inc. as President and Chief Executive Officer in 2013, bringing experience in commercial operations, business development and preparing biopharmaceutical companies for product approval and commercialization. Mr. Leuchtenberger most recently served as President, CEO and a member of the board of directors at Rib-X Pharmaceuticals (now Melinta) until its acquisition. Prior to Rib-X, Mr. Leuchtenberger served as President and CEO of Targanta Therapeutics Corporation, where he led the company’s initial public offering in 2007 and its acquisition in 2009. He served as the President & CEO of Therion Biologics from 2002 to 2006. Mr. Leuchtenberger also served as Vice President of International of Biogen from 1999 to 2002, where he expanded international commercial operations to fifteen countries and distributor sales to 50 countries. He joined Biogen in 1990 as Product Manager and was responsible for managing the late-stage development, registration, marketing and North American launch of the company’s first commercial product Avonex®, now a $3 billion product. During his tenure at Biogen, he held several senior positions, including VP of Sales, Marketing and Business Development where he oversaw Biogen‘s global market, licensing and strategic partnership activities. Prior to Biogen, he served as a Senior Consultant of Bain & Co. specializing in healthcare. He is a past Chairman of the MassBio Board of Directors and currently serves as a trustee of Beth Israel Deaconess Medical Center in Boston. He is a cofounder of Albor Biologics and Alvos Therapeutics (acquired by Arrowhead Research Corp). Mr. Leuchtenberger holds an MBA from the Yale School of Management and a BA in English from Wake Forest University.